Cell News and Research

RSS

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Micromet, Inc. today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive acute lymphoblastic leukemia were published in the May 16th on-line edition of the Journal of Clinical Oncology.

18 May 2011

Mobile phones could help improve diabetes management in under-developed countries

A new study by the Veterans Affairs Ann Arbor Healthcare System and University of Michigan suggests that mobile phones could help low-income patients across the globe manage diabetes and other chronic diseases.

18 May 2011

Intermittent hypoxia enhances cancer growth in mouse model of obstructive sleep apnea

A new study links the intermittent interruption of breathing that occurs in patients with obstructive sleep apnea to enhanced proliferation of melanoma cancer cells and increased tumor growth in mice, according to researchers in Spain.

18 May 2011

African-American children have poor lung function at their initial visit to asthma specialist

African-American children are more likely to report previous emergency room visits, hospitalizations and need for intensive care unit management for asthma than Caucasian children on their first visit to an asthma specialist, according to a study conducted by researchers at Johns Hopkins University.

18 May 2011

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

Cytheris SA and the Cancer Immunotherapy Trials Network, a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center headquartered at Fred Hutchinson Cancer Research Center, Seattle, Washington, today announced the selection of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, as one of the first immunotherapeutic agents proposed for initial clinical trials at network institutions.

18 May 2011

NCNPR and Cancer Institute in Jackson partner for anti-cancer drug research

A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi's National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.

18 May 2011

Novel gene associated with heart development and aging process

Researchers at the University of Ottawa Heart Institute (UOHI) have identified a novel gene in the nucleus of muscle and brain cells that affects heart development and the aging process. Their investigation brings the promise of new treatments for an old, failing heart.

18 May 2011

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

Impaired ability to handle oxidative stress may contribute to asthma development

An impaired ability to handle oxidative stress that arises from exposure to secondhand smoke and other environmental triggers may contribute to the development of asthma, according to results obtained from the Shanghai Women's Health Asthma and Allergy Study. The results of the study suggest regulating the body's antioxidant defense system may play an important role in asthma prevention.

18 May 2011

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin, during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C.

18 May 2011

Leucine deprivation triggers apoptosis in melanoma cells

Whitehead Institute researchers have found that depriving human melanoma cells of the essential amino acid leucine can be lethal to the cells, suggesting a possible strategy for therapeutic intervention.

18 May 2011

Study offers new understanding of cell signaling networks tied to diabetes and cancer

Researchers at the University of Texas Medical Branch at Galveston and the University of California-San Diego School of Medicine have published a study that offers a new understanding of a protein critical to physiological processes involved in major diseases such as diabetes and cancer. This work could help scientists design drugs to battle these disorders.

18 May 2011

Cytonet receives FDA orphan drug designation for liver cell infusion to treat urea cycle disorders

International biotechnology firm Cytonet, which is investigating a liver cell infusion of donated human liver cells for the treatment of urea cycle disorders in young children, announced it has been granted orphan drug designation by the U.S. Food and Drug Administration.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

Teva, ERYtech Pharma sign long term distribution agreement for Graspa in Israel

ERYtech Pharma is pleased to announce it has signed an exclusive long term agreement with Teva for the registration, marketing, distribution and sale of Graspa, the company's lead product, in Israel.

18 May 2011

Anti-cancer drug discovery partnership formed between UMMC Cancer Institute and Natural Products Center

A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi’s National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.

18 May 2011

Excaliber subsidiary merges with VistaGen

Excaliber Enterprises, Ltd. announced today that its wholly-owned subsidiary has merged with VistaGen Therapeutics, Inc., a private biotechnology company focused on stem cell-based drug rescue and drug development. As a result of the Merger, VistaGen is a wholly-owned subsidiary of Excaliber.

17 May 2011

First fully integrated wireless monitoring kit for post-surgery applications compatible with NFC cell phones

GENTAG, Inc., Third Technology Capital Investors, and The CORE Institute are pleased to announce the first fully integrated medical grade wireless monitoring kit for post-surgery applications compatible with the new generation of Near Field Communications (NFC) cell phones. The kit allows patients to self-monitor for excessive swelling in the surgery area or inside casts with their cell phones after hospital discharge (compartment syndrome monitoring).

17 May 2011

CryoLife acquires Cardiogenesis

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has successfully completed its acquisition of Cardiogenesis Corporation.

17 May 2011

Early exposure to social deprivation and neglect linked to prematurely shortened telomeres in children

Studies in institutionalized Romanian children have found that the length of time spent in conditions of social deprivation and neglect correlates with lower IQ and behavioral problems. A new study, led by researchers at Children's Hospital Boston and Tulane University, shows that early adversity even affects children's chromosomes – prematurely shortening the chromosome tips, known as telomeres, and hastening how quickly their cells "age."

17 May 2011

Cell News and Research

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Mobile phones could help improve diabetes management in under-developed countries

Intermittent hypoxia enhances cancer growth in mouse model of obstructive sleep apnea

African-American children have poor lung function at their initial visit to asthma specialist

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

NCNPR and Cancer Institute in Jackson partner for anti-cancer drug research

Novel gene associated with heart development and aging process

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Impaired ability to handle oxidative stress may contribute to asthma development

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Leucine deprivation triggers apoptosis in melanoma cells

Study offers new understanding of cell signaling networks tied to diabetes and cancer

Cytonet receives FDA orphan drug designation for liver cell infusion to treat urea cycle disorders

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

Teva, ERYtech Pharma sign long term distribution agreement for Graspa in Israel

Anti-cancer drug discovery partnership formed between UMMC Cancer Institute and Natural Products Center

Excaliber subsidiary merges with VistaGen

First fully integrated wireless monitoring kit for post-surgery applications compatible with NFC cell phones

CryoLife acquires Cardiogenesis

Early exposure to social deprivation and neglect linked to prematurely shortened telomeres in children

What are the challenges of cell line development? eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics